Nothing Special   »   [go: up one dir, main page]

BR0116994A - An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs - Google Patents

An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs

Info

Publication number
BR0116994A
BR0116994A BR0116994-7A BR0116994A BR0116994A BR 0116994 A BR0116994 A BR 0116994A BR 0116994 A BR0116994 A BR 0116994A BR 0116994 A BR0116994 A BR 0116994A
Authority
BR
Brazil
Prior art keywords
fdc
composition
improved process
fixed dose
preparing
Prior art date
Application number
BR0116994-7A
Other languages
Portuguese (pt)
Inventor
Himadri Sen
Kour Chand Jindal
Kishor Dattatray Deo
Krishnakant Tulsiram Gandhi
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR0116994A publication Critical patent/BR0116994A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UM PROCESSO APERFEIçOADO PARA A PREPARAçãO DE UMA COMPOSIçãO QUE ABRANGE UMA COMBINAçãO DE DOSE FIXA (FDC) DE QUATRO DROGAS ANTITUBERCULOSE". A saber a rifampicina, a isoniazida, a pirazinamida e o cloridrato de etambutol, o qual melhora a dissolução da droga rifampicina, de baixa solubilidade, e assim melhora sua biodisponibilidade. Proporciona ainda um processo aperfeiçoado para a preparação de uma composição que abrange uma combinação de dose fixa (FDC) de quatro drogas antituberculose, a saber a rifampicina, a isoniazida, a pirazinamida e o cloridrato de etambutol, o qual melhora a dissolução da droga rifampicina, de baixa solubilidade, e assim melhora sua biodisponibilidade sem, no entanto, usar qualquer agente surfactante."AN IMPROVED PROCESS FOR PREPARING A COMPOSITION COVERING A FIXED DOSE (FDC) COMBINATION OF FOUR ANTITUBERCULOSIS DRUGS". Namely rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride, which improves the dissolution of the low solubility rifampicin drug and thus improves its bioavailability. It further provides an improved process for the preparation of a composition comprising a fixed dose combination (FDC) of four antituberculosis drugs, namely rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride, which improves rifampicin drug dissolution. , of low solubility, and thus improves its bioavailability without, however, using any surfactant.

BR0116994-7A 2001-04-27 2001-04-27 An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs BR0116994A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000093 WO2002087547A1 (en) 2001-04-27 2001-04-27 An improved process for preparation of four-drug anti-tubercular fixed dose combination

Publications (1)

Publication Number Publication Date
BR0116994A true BR0116994A (en) 2004-03-02

Family

ID=11076344

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116994-7A BR0116994A (en) 2001-04-27 2001-04-27 An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs

Country Status (2)

Country Link
BR (1) BR0116994A (en)
WO (1) WO2002087547A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046567A2 (en) * 2003-09-10 2005-05-26 Meena Shelgaonkar Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
EP1711182A1 (en) * 2004-02-04 2006-10-18 Vinay Ramakant Sapte Oral cyclodextrin complexes of antituberculosis drugs
WO2005107740A1 (en) * 2004-05-07 2005-11-17 Vinay Ramakant Sapte Enhancing the efficacy of tubercular drugs by combination with alpha tocopherol
WO2005107741A1 (en) * 2004-05-07 2005-11-17 Vinay Ramakant Sapte Novel oral compositions comprising antitubercular drugs in combination with alpha-tocopherol
EP1737847B1 (en) 2004-07-30 2008-06-04 Torrent Pharmaceuticals Ltd Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
RU2423977C1 (en) * 2010-04-20 2011-07-20 Открытое Акционерное Общество "Фармасинтез" Anti-tuberculosis medication based on 4-thioureidoiminomethylpyridinium perchlorate, method of its obtaining and method of treatment
WO2012013756A2 (en) 2010-07-28 2012-02-02 Laboratoires Pharma 5 Method for preparing tablets combining rifampicin, isoniazid, pyrazinamide and, optionally, ethambutol
FR2963236B1 (en) * 2010-07-28 2013-03-01 Pharma 5 Lab PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING RIFAMPICIN, ISONIAZIDE, PYRAZINAMIDE AND, IF POSSIBLY, ETHAMBUTOL
US8470365B2 (en) 2010-07-29 2013-06-25 Taiwan Biotech Co., Ltd. Process for preparation of anti-tubercular combination and pharmaceutical composition prepared therefrom
CN102727496A (en) * 2011-04-12 2012-10-17 上海双健现代药物技术咨询有限公司 Compound antituberculosis drug oral solid preparation and its preparation method
CN102579447B (en) * 2011-12-31 2014-10-15 沈阳药科大学 Preparation method for anti-tuberculosis medicinal compound preparation
CN102920707B (en) * 2012-11-02 2014-10-29 沈阳药科大学 Process for preparing compound antituberculous preparation
MX2016001156A (en) * 2013-07-26 2016-04-29 Sanofi Sa Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
JP2016539110A (en) * 2013-07-26 2016-12-15 サノフイ Anti-tuberculosis stable pharmaceutical composition in the form of dispersible tablets containing isoniazid granules and rifapentine granules and a process for producing the same
SG10201800447UA (en) * 2013-07-26 2018-02-27 Sanofi Sa Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
CN104706638A (en) * 2015-02-04 2015-06-17 上海华源安徽仁济制药有限公司 Compound rifampin capsules and preparation method thereof
EP3578167A1 (en) * 2018-06-04 2019-12-11 Universitat de Barcelona Suspension formulation for the treatment of tuberculosis
CN110169954B (en) * 2019-06-20 2021-10-15 江苏四环生物制药有限公司 Stable-dissolution pyrazinamide tablet and preparation method thereof
CN110200933A (en) * 2019-07-11 2019-09-06 重庆华邦制药有限公司 It is used to prepare the composition and its preparation method and application for treating phthisical three compound preparation
CN113694067B (en) * 2021-09-30 2023-12-01 齐齐哈尔医学院 Microsphere sustained release preparation carrying isoniazid and rifampicin together and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916417A1 (en) * 1989-05-19 1990-11-22 Saarstickstoff Fatol Gmbh COMBINATION PREPARATIONS CONTAINED RIFAMPICIN AND THIOACETAZONE AND, WHERE APPROPRIATE, ISONICOTINSAEURE HYDRAZIDE AS ACTIVE ACTIVE SUBSTANCES
IT1289883B1 (en) * 1996-10-09 1998-10-19 Lupin Lab Ltd ANTI-TUBERCULAR PHARMACEUTICAL COMPOSITION AND PROCEDURE FOR ITS PRODUCTION

Also Published As

Publication number Publication date
WO2002087547A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
BR0116994A (en) An improved process for preparing a composition comprising a fixed dose combination (fdc) of four antituberculosis drugs
WO2002081453A8 (en) Thiohydantoins and use thereof for treating diabetes
BR0215184A (en) orally active taxane derivative pharmaceutical compositions having increased bioavailability
CY1106150T1 (en) METHODS FOR THE PREPARATION OF OPTICALLY PURE (R)- AND (S)-DIDESMETHYLOSIBUTRAMINE
AU2002316811A1 (en) Stable formulation of modified glp-1
ATE513541T1 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF CALCITONIN
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
GEP20043287B (en) Pharmaceutical Composition Containing Fenofibrate and Method for Its Production
MXPA04003569A (en) Biphasic mixtures of glp-1 and insulin.
DE60019693D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE ABSORPTION-CONNECTING COMPOUNDS
PT1033981E (en) FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS
WO2002074247A3 (en) Pharmaceutical formulations for sustained release
ATE401890T1 (en) CONTROLLED RELEASE FORMULATION CONTAINING LAMOTRIGINE
JP2002510633A5 (en)
WO2000032186A3 (en) Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
PL376176A1 (en) Solid preparation
EP1558931A4 (en) Analysis of pharmaceutical solubility and stability
NO20040598L (en) 5-CNAC as an oral delivery agent for parathyroid hormone fragments.
MXPA05012955A (en) Pharmaceutical compositions of atorvastatin.
MXPA04003520A (en) Pharmaceutical formulation comprising (r) -bicalutamide.
WO2002070014A8 (en) Compositions comprising an o/w emulsion containing conjugated linoleic acid
ES2194129T3 (en) PHARMACEUTICAL COMPOUNDS.
GEP20043377B (en) Pharmaceutical Complex
ECSP045232A (en) ORAL DOSAGE FORM, PROCEDURE TO PREPARE IT AND USE OF A PHARMACEUTICALLY ACCEPTABLE WEAK BASE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE OF THE SAME TO PREPARE SUCH ORAL DOSAGE FORM

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 3A ANUIDADE(S), DE ACORDO COM A TABELA VIGENTE, REFERENTE A(S) GUIA(S) NO 300240362232 E COMPROVAR O RECOLHIMENTO REFERENTE A RESTAURACAO DA 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM O ART.34 "II" DA LPI (LEI 9279, DE 14/05/96), O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]